Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
10.12.2020 16:00:00 EET | Business Wire | Press release
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio.
“NBE-Therapeutics’ iADC platform adds exceptional tumor targeting capabilities to our oncology portfolio. Together with our immune cell-targeting assets, this could enable new powerful combinations that will allow for efficacious and durable treatments for patients,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “This acquisition is a further example of Boehringer Ingelheim’s long-term strategy to enhance our position as an innovator of novel cancer therapies for patients in need. We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work.”
The total transaction value is 1.18 billion euros and also includes contingent clinical and regulatory milestones.
“I am extremely proud of the NBE-Therapeutics’ team and delighted that our world class ADC expertise is being recognized by Boehringer Ingelheim. This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics. “We look forward to progressing NBE-002, our lead program and best-in-class anti ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities.”
Boehringer Ingelheim’s cancer cell directed research is focused on the development of targeted therapies for the treatment of difficult-to-treat solid tumors. Inducing tumor cell death is a key component, and ADC based approaches have emerged as a powerful targeted therapy with potential for induction of immunogenic cell death at reduced systemic exposure and toxicity.
The NBE-Therapeutics’ acquisition will significantly strengthen Boehringer Ingelheim’s strategic focus on targeted cancer cell-directed therapies and complements existing capabilities in antigen discovery as well as antibody and T-cell engager technologies. By combining its world-class, in-house research and development with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative therapies and accelerating the delivery of the next generation of cancer treatments. This builds on recent strategic acquisitions and collaborations, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are also contributing assets.
NBE-Therapeutics is headquartered in Basel, Switzerland, where it was founded with financial backing from a syndicate of both corporate and institutional investors, including the Boehringer Ingelheim Venture Fund, and PPF Group, as their largest shareholders, and Denmark’s Novo Holdings. NBE-Therapeutics’ technology platform and derived assets are protected by a broad portfolio of patents and licenses.
The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-nbe-therapeutics
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005538/en/
Contact information
NBE-Therapeutics
Bertrand Damour, CEO
E: bertrand.damour@NBE-Therapeutics.com
NBE-Therapeutics media enquiries:
Optimum Strategic Communications
Mary Clark, Manel Mateus, Elakiya Rangarajah
T: +44 (0) 20 3922 0900
E: NBE-Therapeutics@optimumcomms.com
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Second to None in Business Excellence: Mary Kay Named #2 on the Forbes 2026 Best Customer Service List10.2.2026 18:01:00 EET | Press release
Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. The honor follows a standout year for Mary Kay, which concluded 2025 with a total of 25 global awards, underscoring its continued focus on corporate excellence, direct selling industry, social impact, environmental sustainability, science, and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210599426/en/ Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. (Image Courtesy: Mary Kay Inc.) The recent recognition highlights Mary Kay’s enduring commitment to putting the customer at the heart of everything it does, from seamless digital
Interactive Brokers Expands Crypto Futures Offering with Coinbase Derivatives10.2.2026 17:15:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Coinbase Derivatives, LLC nano Bitcoin and nano Ether futures contracts for trading on the IBKR platform. These new products are available with monthly expirations or as perpetual-style contracts, offering eligible clients a cost-effective way to gain exposure to cryptocurrency and manage risk within a regulated framework, with trading available 24/7. Clients of Interactive Brokers can access more than 170 markets worldwide and trade both traditional instruments and digital assets from a single platform. The new Coinbase Derivatives contracts offer an easier way to manage cryptocurrency exposure, with lower capital requirements and transparent trading on a regulated exchange. Nano futures are smaller-sized contracts, such as 0.01 Bitcoin and 0.10 Ether, that lower entry costs and allow for more precise position sizing. Perpetual-style futures are long-dated contracts that are design
Andersen Consulting Adds Lighthouse Consultants10.2.2026 16:30:00 EET | Press release
Andersen Consulting enters a Collaboration Agreement with Lighthouse Consultants, a London-based consulting firm specializing in forensic accounting and financial investigations. Founded by Managing Director Kingsley Bye, Lighthouse Consultants provides services including fraud and financial crime investigations, bribery and corruption inquiries, litigation and insurance claims analysis, financial analysis, risk assessments, internal and compliance reviews, and sustainability audits. The firm’s team of experienced chartered management accountants works with law firms, high-net-worth individuals, businesses, and charities to resolve complex disputes, mitigate risks, and enhance transparency across financial and operational processes. "By integrating our forensic and investigative expertise with Andersen’s global platform, we can deliver a more comprehensive suite of services that addresses clients’ needs from risk prevention to complex dispute resolution,” Kingsley said. “This collabora
Draslovka and Avathon Partner to Deliver AI-Powered Solutions for Mining Through Autonomy, MetOptima and Blue Cube Combined Offering10.2.2026 16:00:00 EET | Press release
Draslovka a.s. (“Draslovka”), a global innovator in sustainable chemical technologies and AI‑enabled services for the mining sector, and Avathon, the leader in Autonomy for Operations, today announced a strategic commercial partnership to accelerate the adoption of intelligent, autonomous, and data‑driven operations across the global mining industry. The partnership provides a breakthrough solution that combines Draslovka’s real‑time mineral and slurry monitoring technologies—delivered through its world class Blue Cube on‑stream mineralogical sensors—and MetOptima advanced metallurgical optimization AI engine, with the Avathon Autonomy Platform, a scalable industrial‑AI environment that enhances operational performance, automating decisions, and orchestrating complex operations across sites. Under the agreement, Draslovka and Avathon will collaborate closely on go-to-market initiatives, jointly commercializing and cross‑selling the combined offering. The combined Draslovka‑Avathon offe
Golub Capital Expands Broadly Syndicated Loan CLO Business to Europe10.2.2026 16:00:00 EET | Press release
Today, Golub Capital (“the Firm”) announced the expansion of its BSL CLO strategy to Europe and the appointment of Tyler Wallace as Managing Director, European Broadly Syndicated Loans. Wallace brings more than 20 years of leading credit experience to the Firm and most recently was a Managing Director and Portfolio Manager of CLOs at Fair Oaks Capital in London. “This is a natural expansion for us,” said Scott Morrison, Head of BSL at Golub Capital. “The expansion builds on our market-leading U.S. CLO platform and strengthens our ability to deliver comprehensive financing solutions to partners across Europe.” Said Tyler Wallace, “Golub Capital has an exceptional BSL track record. I am excited to lead this next chapter and bring the Firm’s capabilities to partners in the region.” As of December 31, 2025, Golub Capital manages over $14 billion in broadly syndicated loans and has completed over 60 BSL CLO transactions since 2007. Other key business highlights include: Closed over $9 billi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom